Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule

• Published in: European journal of clinical pharmacology 1998-11, Vol.54 (9-10), p.677-683
• Main Authors: PERDAEMS, N, BACHAUD, J. M, ROUZAUD, P, MURRIS-ESPIN, M, HERMANT, C, MIHURA, J, LOCHON, I, HOUIN, G, CANAL, P, CHATELUT, E
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - blood; Antineoplastic Agents, Phytogenic - pharmacokinetics; Area Under Curve; Bayes Theorem; Biological and medical sciences; Blood Proteins - metabolism; Chromatography; Computer programs; Drug toxicity and drugs side effects treatment; Equilibrium dialysis; Etoposide; Etoposide - adverse effects; Etoposide - blood; Etoposide - pharmacokinetics; Female; High-performance liquid chromatography; Humans; Male; Medical sciences; Middle Aged; Neoplasms - blood; Neoplasms - drug therapy; Neoplasms - metabolism; Neutropenia; Pharmacokinetics; Pharmacology. Drug treatments; Plasma; Plasma proteins; Prospective Studies; Protein Binding; Sampling; Toxicity; Toxicity: blood
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/s002280050534

This study was undertaken in order to evaluate the impact of pharmacokinetics on the toxicity of oral etoposide administered daily for 21 days. The daily dose was 50 mg/m2. Thirty-two patients 24 males and eight females, 36 76 years old, treated for various tumour types), were evaluated. Blood samples were obtained on day 1 for all patients, and on day 21 for 16 patients. Plasma etoposide concentrations were determined by high-performance liquid chromatography, and etoposide plasma protein binding by equilibrium dialysis. On day 1, the mean value (with coefficient of variation for interindividual variability) for the unbound fraction (fu), area under the concentration versus time curve (AUC), and unbound AUC was 9.8% (59%), 34 mg x h/l (39%), and 3.5 mg x h/l (92%), respectively. The ratio between AUC on day 1 and day 21 ranged between 0.5 and 1.8 (mean 0.9, with CV 33%). The plasma trough unbound concentrations and the unbound AUCs both corresponding to the first administration were significantly higher in the 11 patients who had a severe neutropenia than in the 21 patients who had no or moderate toxicity. However, total etoposide concentrations did not differ between these two groups. A limited sampling strategy using the NONMEM program and a database of 89 patients previously studied was performed. The optimal sampling schedule (i.e. 1, 4, and 24 h after oral etoposide administration) allowed to obtain the AUC accurately on day 1. Individual adjustment of oral etoposide based on unbound pharmacokinetics after the first administration appears relevant and feasible.